Increased baseline profibrotic activity was observed in patients with HFrEF and a greater reduction in CV death or hospitalization for HF, the greater the decrease in soluble tumorigenicity suppressor 2 (sST2) or metallopeptidase inhibitor 1 (TIMP-1) compared to baseline levels (49). The gene discussed is IL1RL1; the disease is hydrops fetalis.